AI in Drug Discovery
A Generative Model Designed This KRAS Inhibitor. It's Now in Patients.
ALD-9102 was never screened from a physical library — it was sampled from a diffusion model trained on covalent fragment geometries. Eleven weeks later, it had a crystal structure. Fourteen months later, it had a Phase 1 trial.